PROCEPT BioRobotics Corp(PRCT)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Rank #2,394 of 2,961 stocks
Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.
Revenue Growth
Profitability
Balance Sheet
Earnings Quality
Free Cash Flow
Institutional Flow
Revenue Scale
Dilution Risk
PRCT Stock Analysis & AI Quality Score
Data updated 2026-09-11AI stock analysis and institutional research for PROCEPT BioRobotics Corp (PRCT), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores PRCT at 33.3/100 on a 32-signal composite quality model, placing it at rank #2,394 of 2,961 stocks — the bottom half of the AI-ranked universe. PRCT scores in the top quartile across revenue growth (92.1). Areas of concern include balance sheet strength (10.3) and free cash flow (12.0), which score below median versus the broader universe. Shareholder dilution risk is elevated at 11.6/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), PROCEPT BioRobotics Corp reports quarterly revenue of $94.5M, net income of $-26.9M, an operating margin of -29.0%. Top institutional holders of PRCT by reported 13-F value include BlackRock, T. Rowe Price Investment Management, BNP Paribas Asset Management Holding S.A., based on the most recent SEC filings. PRCT trades on the Nasdaq exchange and files with the SEC under CIK 1588978. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate PRCT daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for PROCEPT BioRobotics Corp directly from SEC EDGAR. PROCEPT BioRobotics Corp's 13F Pro composite quality score has ranged between 27 and 41 since 2022, currently 33.3 — a declining long-term trajectory across 64 quarterly and live scoring snapshots.
Revenue
Q2 2026
$94.5M
Net Income
Q2 2026
$-26.9M
Free Cash Flow
Q2 2026
$-22.2M
Operating Margin
Q2 2026
-29.0%
ROIC
Q2 2026
-28.0%
D/E Ratio
Q2 2026
0.15
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProRevenue
+37.2% YoYNet Income
-4.5% YoYOperating Income
-7.5% YoYEPS (Diluted)
+1.7% YoYTotal Assets
-4.9% YoYTotal Debt
+0.3% YoYOp. Cash Flow
+50.6% YoYFree Cash Flow
+43.7% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $308.1M +37.2% | $224.5M +64.8% | $136.2M +81.6% | $75.0M +117.6% | $34.5M +346.7% | $7.7M |
| Net Income | $-95.6M -4.5% | $-91.4M +13.7% | $-105.9M -21.5% | $-87.2M -45.6% | $-59.9M -12.9% | $-53.0M |
| Operating Income | $-103.9M -7.5% | $-96.6M +11.5% | $-109.2M -35.2% | $-80.7M -49.0% | $-54.2M -13.3% | $-47.8M |
| EPS (Diluted) | $-1.72 +1.7% | $-1.75 +21.9% | $-2.24 -14.3% | $-1.96 +46.0% | $-3.63 +74.9% | $-14.47 |
| Total Assets | $508.1M -4.9% | $534.0M +31.9% | $404.7M +30.8% | $309.3M -8.2% | $337.0M +167.5% | $126.0M |
| Total Debt | $51.6M +0.3% | $51.5M +0.3% | $51.3M +0.2% | $51.2M +2.4% | $50.0M -6.6% | $53.5M |
| Operating Cash Flow | $-49.0M +50.6% | $-99.2M +8.1% | $-108.0M -34.4% | $-80.4M -40.2% | $-57.3M -18.6% | $-48.3M |
| Free Cash Flow | $-58.3M +43.7% | $-103.6M +22.2% | $-133.2M -60.4% | $-83.0M -43.3% | $-57.9M -19.2% | $-48.6M |
Get alerted when PRCT's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for PROCEPT BioRobotics Corp including:
Top Institutional Holders of PRCT
BlackRock, Inc.
$110.0M4,869,828 shT. Rowe Price Investment Management, Inc.
$73.7M3,265,704 shBNP Paribas Asset Management Holding S.A.
$63.8M2,823,849 shVANGUARD PORTFOLIO MANAGEMENT LLC
$57.1M2,526,802 shVANGUARD CAPITAL MANAGEMENT LLC
$55.6M2,460,802 shChicago Capital, LLC
$46.8M2,073,237 shSTATE STREET CORP
$36.5M1,617,475 shGEODE CAPITAL MANAGEMENT, LLC
$33.5M1,484,163 shFMR LLC
$32.6M1,444,878 shPRICE T ROWE ASSOCIATES INC /MD/
$30.1M1,332,452 sh
| Fund | Value | Shares |
|---|---|---|
| BlackRock, Inc. | $110.0M | 4,869,828 |
| T. Rowe Price Investment Management, Inc. | $73.7M | 3,265,704 |
| BNP Paribas Asset Management Holding S.A. | $63.8M | 2,823,849 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $57.1M | 2,526,802 |
| VANGUARD CAPITAL MANAGEMENT LLC | $55.6M | 2,460,802 |
| Chicago Capital, LLC | $46.8M | 2,073,237 |
| STATE STREET CORP | $36.5M | 1,617,475 |
| GEODE CAPITAL MANAGEMENT, LLC | $33.5M | 1,484,163 |
| FMR LLC | $32.6M | 1,444,878 |
| PRICE T ROWE ASSOCIATES INC /MD/ | $30.1M | 1,332,452 |
Companies Similar to PRCT
Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.
GeneDx Holdings Corp.
Syndax Pharmaceuticals Inc
Twist Bioscience Corp
ORTHOPEDIATRICS CORP
Alphatec Holdings, Inc.
ARS Pharmaceuticals, Inc.
RHYTHM PHARMACEUTICALS, INC.
Beta Bionics, Inc.
Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.
More Healthcare Companies
View all Healthcare →Put PRCT on your watchlist
Track score changes the day PROCEPT BioRobotics Corp files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is PRCT a good stock to buy?
13F Pro's AI-powered analysis of PROCEPT BioRobotics Corp (PRCT) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for PRCT are available on the PRCT stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. PRCT is classified as a small company.
Which hedge funds own PRCT?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling PRCT. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of PROCEPT BioRobotics Corp's investment landscape.